Access Biotech China: What to Expect?
The first edition of Access Biotech China (ABC) is planned on 14-15 October 2021 as an hybrid event. Access Biotech China aims to help European Life Sciences & Health companies to explore and seize the many opportunities that the Chinese biotech sector has to offer. The focus will not only be on accessing the market and entering partnering opportunities, but also on getting access to the Chinese financial market and investors.
China is rapidly becoming increasingly attractive for biotechs looking for additional investment, partnerships and customers. Not only does China have a massive population and a correspondingly large patient group, the phenomenal economic growth, government reforms and huge investments have turned the Chinese biopharmaceutical market into the second largest in the world with $137 billion in sales last year.
The importance of the biotech industry has been recognised by the Chinese Government. It has recently introduced changes in regulations to make it much easier and quicker for drugs developed by foreign companies to be approved and sold in China, but also for Chinese VCs to seek out promising foreign investments. While there are still more cross-border investments from China to the US than there are between China and Europe, interest in European biotech is growing rapidly.
China: mission possible!
Due to the complexity of policies on different market segments, the vastness of the country and the different (business) culture and language, it can almost seem like a mission impossible to enter the Chinese market successfully for foreign companies with limited or no experience in doing business there. Entry of the Chinese market requires tailor-made strategies. There is not a 'one-size-fits-all' approach.
Access Biotech China aims to give you the abc of how to take the first steps to enter the Chinese biotech sector. Besides giving you insight in the opportunities that China has to offer for you as a biotech company, it will also give you insight in some of the key challenges and provide you with practical recommendations that will help you to develop a China market entry strategy. In addition, ABC will bring you in touch with organisations that can help you achieve that.
Programme
Day 1 of Access Biotech China will be in-person at BioPartner 5 in Leiden with a livestream to the Virtual Event Platform. This day will focus on Chinese Life Sciences sector, landscape, hubs, opportunities & future expectations, how to partner with Chinese companies and/or investors, the route to market from A to Z and best practices & experience stories, obstacles and lessons learned. Keynote speakers on day 1 include Nico Schiettekatte, Counselor for Health, Welfare & Sport at Embassy of the Kingdom of the Netherlands in China, Dr. Zang Jingwu, CEO at I-MAB Biopharma, Yong Xue, CMO at Asieris Pharmaceuticals, Nettie Buitelaar, CBO at BiosanaPharma and many more.
Day 2 will focus on online expert sessions focussing on funding & venture capital, business development, corporate structuring & compliance, differences in business environment and perspectives and intellectual Property. Besides the expert sessions the second day will offer the opportunity to have one-on-one partnering meetings.
For more information on the programme, visit: https://www.hyphenprojects.nl/abc/program-overview
